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Changing pattern of surgical revascularization for
critical limb ischemia over 12 years: Endovascular
vs open bypass surgery
Toshifumi Kudo, MD, PhD, Fiona A. Chandra, BS, Woo-Hyung Kwun, MD, PhD, Bradley T. Haas,
and Samuel S. Ahn, MD, Los Angeles, Calif
Objective: This study is a review and evaluation of our 12-year experience of revascularization for critical limb ischemia
(CLI) with angioplasty/stenting and bypass surgery to identify specific trends of procedure volume and outcomes in this
particular group.
Methods: Endovascular and open bypass procedures done for CLI by a single surgeon between 1993 and 2004 were
evaluated retrospectively. Thrombolysis and thrombectomy procedures done as the only revascularization procedure were
excluded from analysis. The data were divided into three groups by time periods: the first period, 1993 to 1996; the
second period, 1997 to 2000; and the third period, 2001 to 2004. Outcomes were defined according to the reporting
standards of the Society for Vascular Surgery/International Society for Cardiovascular Surgery. The study included 416
procedures done in 237 limbs in 192 patients. The mean follow-up was 23 months (range, 1 to 122 months).
Results: Primary revascularization procedures for CLI were angioplasty in 153 limbs (65%) and bypass surgery in 84
(35%). Subsequent procedures were angioplasty in 102 limbs (57%) and open surgery (bypass and/or patch angioplasty)
in 77 limbs (43%). The rates for technical and clinical success and complications in the entire group were 99%, 95%, and
4%, respectively. One patient died perioperatively (0.5%). Among the three periods, TransAtlantic Inter-Society
Consensus lesion types were significantly more severe in patients in the first period (P < .05). Additionally, the
complication rate was significantly higher and the mean hospital stay was significantly longer in the first period compared
with the second and third periods (P < .05). Furthermore, between the first and third periods, the number of
endovascular revascularization procedures done as primary and secondary procedures significantly increased from 15 to
84 (460%) and from 13 to 57 (340%), whereas the number of open surgical procedures done as primary and secondary
procedures decreased from 39 to 20 (49%) and from 35 to 18 (49%), respectively (P < .0001). The assisted primary
patency rates in the third period were significantly higher than those in the first and second periods (P .012); otherwise,
the long-term outcomes among the three periods were not statistically different. Multivariate analysis revealed that, while
controlling for other factors, the third period showed improvement in the primary patency (P  .032) and assisted
primary patency (P  .051), and the bypass group showed improvement in the primary patency (P  .008).
Conclusions: In our experience, open surgical procedures for the treatment of CLI have been largely replaced by
angioplasty procedures without compromising outcomes. Angioplasty is a feasible, safe, and effective procedure and can
be the procedure of choice for the primary and secondary treatment of CLI. Open surgical procedures can be reserved for
lesions technically unsuitable for endovascular procedures and patients who do not demonstrate clinical improvement
after angioplasty. ( J Vasc Surg 2006;44:304-13.)Critical limb ischemia (CLI) has been considered as a
primary indication for bypass surgery.1-3 In recent years,
however, there have been notable continuing advances
in imaging techniques, angioplasty equipment, and en-
dovascular techniques that allow for the increasing use of
angioplasty with or without stenting as a primary revas-
cularization procedure for CLI.4,5 Many reports have
also supported the effectiveness of angioplasty in the
treatment of patients with CLI, and the lower morbidity
and cost, and results comparable to those of surgical
bypass, support the increasingly significant role of angio-
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304plasty in the management of patients with CLI.4-10 To
our knowledge, only one published study has reported
about the trend of types of procedures used in the
treatment of patients with CLI.4 The aim of this study is
to review our 12-year experience in the treatment for
CLI with endovascular and bypass surgery to identify the
specific changing pattern of the practice characteristics,
surgical volume, and outcomes.
METHODS
Patient population. We reviewed the records of pa-
tients at the University of California at Los Angeles Divi-
sion of Vascular Surgery who underwent either open bypass
surgery or angioplasty with or without stenting as their
primary or subsequent revascularization procedures for
CLI. All procedures were performed by a single vascular
surgeon for the treatment of chronic occlusive disease of
the aortoiliac, femoral, popliteal, or tibial arteries, or a
combination, between January 1993 and December 2004.
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only revascularization procedure were excluded.
The study included 416 procedures done in 237 limbs
in 192 patients performed during this time interval. All
patients had evidence of chronic CLI, defined as rest pain
by the Society for Vascular Surgery (SVS)/International
Society for Cardiovascular Surgery (ISCVS) (clinical cate-
gory 4) or ulcer/gangrene (category 5), and were included
in this retrospective cohort study.11 Preoperative, intraop-
erative, and follow-up information was available for all
patients; this information was obtained from office and
hospital chart reviews and dictated operative records. The
study protocol was approved by the local institutional re-
view board.
The decision to proceed with angioplasty or surgical
bypass as a treatment modality was determined from a
review of each patient’s clinical history, physical examina-
tion, noninvasive laboratory findings, and angiography
findings done on the same day of the procedure by a
vascular surgeon.11 Selection of procedure types has
changed over the years and was based on advances in
endovascular technology such as closure devices, stents,
0.018-inch-sized systems, and slippery hydrophilic guide-
wires, and the primary surgeon’s endovascular skills. There
was no particular anatomic location of a lesion that ex-
cluded endovascular intervention. Currently, symptomatic
occlusive lesions in lower extremities are treated with en-
dovascular procedures if it is technically possible.
Our approach to revascularization in patients with le-
sions in multiple levels was as follows:
1. In patients with severe iliac, femoropopliteal, or both
(proximal) lesions and mild or moderate femoropopli-
teal, tibial, or both (distal) lesions, the proximal (inflow)
lesions were treated first without distal (outflow) bypass
or angioplasty.
2. In patients with primarily femoropopliteal, tibial, or
both (distal) lesions, the distal (outflow) lesions were
treated with bypass or angioplasty with concomitant
proximal (inflow) bypass or angioplasty as needed.
Stents were selectively placed in patients with iliac
lesions for primary angioplasty failure, including residual
stenosis (30%), pressure gradient (5 mm Hg), or both.
Stent placement in patients with femoropopliteal lesions
was limited to those lesions that did not respond to balloon
dilation alone because of elastic recoil, arterial dissection, or
both. No stent was placed in a tibial lesion.
Before-and-after pressures were routinely measured
with papaverine injection in patients with iliac lesions and
only when the patient had an angiographic problem (ie,
residual stenosis in patients with infrainguinal lesions).
Detailed descriptions of angioplasty and stent techniques
were given in our previous report.6 The use of other
endovascular treatment modalities such as laser angio-
plasty, cryoplasty, and atherectomy was limited in this
series.
Hemodynamic and radiologic evaluation. Ankle-
brachial pressure index (ABI)measurements and duplex scanswere obtained before treatment. Doppler ultrasound wave-
forms were also evaluated. Patients were usually seen 2
weeks after the procedure. Postoperative follow-up (clinical
examination,ABImeasurements, and serial duplex ultrasound
scanning) was conducted every 3 months during the first
postoperative year and every 6 months thereafter.
Indications for repeat intervention included recurrent
symptoms accompanied by a 0.10 increase in ABI over
the preoperative value or recurrent stenosis 60% by du-
plex scanning (a threefold difference in the velocity across
the lesion is estimated as a 60% to 80% stenosis by our
institute’s vascular laboratory). Patients with insufficient
vascular laboratory records were considered lost to fol-
low-up in patency analysis.
Definitions and classifications. The arterial lesions in
the lower extremity were classified by angiographic findings
according to TransAtlantic Inter-Society Consensus
(TASC) critereria.12 The data were tabulated for (1) the
date of procedures (the first period between 1993 and
1996, the second period between 1997 and 2000, and the
third period between 2001 and 2004), and (2) types of the
primary procedures, which were angioplasty with or with-
out stenting (endo group) or surgical bypass (bypass
group). These variables were statistically analyzed and cor-
related with outcomes.
Success of angioplasty and bypass procedures was de-
fined anatomically, hemodynamically, and clinically accord-
ing to SVS/ISCVS13,14 reporting standards:
1. An angioplasty procedure was deemed technically suc-
cessful if there was 30% residual stenosis, and in iliac
lesions, the brachiofemoral pressure gradient was 5
mm Hg.
2. Angioplasty and bypass surgical procedures were con-
sidered as a clinical success or improvement if the symp-
toms improved by at least one clinical category together
with an increase in the ABI of 0.10 over preoperative
values (this constitutes primary clinical success instead of
continued or corrected clinical success after successful
reintervention);
3. Patency was determined by duplex scanning, ABI mea-
surements, or both.
4. All revisions were performed on the basis of the criteria
described previously and occlusions at any lesion on the
same limb were considered a primary angioplasty or
surgical bypass failure.
5. All analysis was performed on an intent-to-treat basis
and thus included initial technical failures.
Statistical analysis. P values for univariate compari-
sons of categoric variables in each group were computed
using exact 2 tests. P values for univariate comparisons of
continuous variables between the two groups were com-
puted via the Student’s t test (normal distribution) or the
Mann-Whitney U test (skewed distribution). Differences
among the three groups were analyzed with the one-way
analysis of variance for normal distribution or the Kruskal-
Wallis test for skewed distribution. Time-to-failure curves
(“survival curves”) for patency, continued clinical improve-
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using the Kaplan-Meier method. Time-to-failure curves
were compared univariately using the log-rank test. Statis-
tical significance was defined as P  .05.
For each outcome, backward stepdown Cox regression
using a P  .055 significance criterion was used estimate
the failure rate ratio and identify the subset of simulta-
neously significant factors from the pool of potential pre-
dictors of that outcome. These included gender, age, co-
morbidities, indications for surgery (rest pain vs ulcer/
gangrene), original ABI, TASC lesion types, the most distal
artery segment treated (iliac vs femoropopliteal vs tibial or
more distal arteries), the study periods, and the primary
procedures in the endo group vs the bypass group. Results
were evaluated and presented in accordance with the sug-
gested reporting standards for lower extremity surgical and
percutaneous procedures of the SVS/ISCVS.13,14
RESULTS
Demographic and treatment information. The
mean follow-up was 23 months (range, 1 to 122) months.
Table I. Characteristics and outcomes of 237 subjects wit
Total




Mean age (years) 69.6  11.9
Comorbidities
Hypertension 161 (68)
Diabetes mellitus 149 (63)
Coronary artery disease 152 (64)
Smoking 107 (45)
Hyperlipidemia 82 (35)
CRF with HD 52 (22)
Cerebrovascular disease 44 (18)
COPD 25 (11)
Indication




Type B 18 (8)
Type C 112 (47)
Type D 107 (45)
The most distal artery treated
Iliac artery 57 (24)
Femoropopliteal artery 84 (34)
Tibial or more distal arteries 96 (42)
ABI ( SD) 0.40  0.24
Technical success 234 (99)
Clinical success 225 (95)
Complication 9 (4)
Mean hospital stay (days) 4.4  6.7
CRF, Chronic renal failure; HD, hemodialysis; COPD, Chronic obstru
Ankle-brachial pressure index.
Values are indicated with percentages (%) or  SD.
*PTA group vs bypass group.
†2 test.
‡Mann-Whitney U test.Clinical characteristics of the patients studied are summa-rized in Table I. Two limbs in two patients had above-ankle
amputations without attempts at angioplasty or bypass
surgery during the study period and are not included. For
the entire patient population, the primary procedures were
angioplasty in 153 limbs (65%) and bypass surgery in 84
(35%); the subsequent procedures included 102 angio-
plasty (57%) and 77 bypass or patch angioplasty procedures
by open surgery (43%) (Appendix I, online only). The
mean number of subsequent procedures was 0.73 per limb.
The overall outcomes (rates SE) at 7 years were 30%
 7% for the primary patency, 60%  8% for the assisted
primary patency, 65% 8% for the secondary patency, 39%
 8% for the continued clinical improvement, and 77% 
7% for the limb salvage (Appendix II,A and B, online only).
The survival rate of the entire patient population was 47%
5% at 5 years.
In the bypass group, 40 limbs (47%) were treated with
prosthetic grafts and 44 (53%) with autologous vein grafts.
Most of the patients treated with prosthetic grafts had
undergone previous surgical bypass in another institution
and underwent redo surgery without available appropriate
tical limb ischemia
Endo group
(n  153) (%)
Bypass group
(n  84) (%) P*
88 (58) 53 (63) .4
65 (42) 31 (37)
70.2  12.4 68.3  10.8 .25
95 (62) 66 (79) .0093†
90 (59) 59 (70) .082
97 (63) 55 (65) .75
62 (41) 45 (54) .053†
56 (37) 26 (31) .38
29 (19) 23 (27) .13
19 (12) 25 (30) .0010†
14 (9) 11 (13) .34
60 (39) 27 (32) .28
93 (61) 57 (68)
0 0 .0001‡
17 (11) 1 (1)
86 (56) 26 (31)
50 (33) 57 (68)
48 (31) 9 (11) .0050‡
50 (33) 34 (40)
55 (36) 41 (49)
0.42  0.25 0.37  0.22 .15
150 (98) 84 (100) .2
143 (93) 82 (98) .16
3 (1) 6 (7) .046†
2.6  4.9 7.7  8.3 .0001‡
ulmonary disease; TASC, TransAtlantic Inter-Society Consensus; ABI,h cri
ctive pautologous vein at our institution. Prosthetic grafts were
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popliteal (19 above the knee and 8 below the knee), and 3
tibial bypasses. Vein grafts were used in 6 below-the-knee
popliteal, 15 proximal tibial, 10 distal tibial, 11 dorsalis
pedis, and 2 plantar bypasses. Forty-one limbs (49%) had
tibial or more distal bypass procedures.
In the endo group, catheter-based angioplasty was
performed at 69 iliac, 80 femoral, 80 popliteal, and 55 tibial
or more distal arteries. Eighty-eight limbs (58%) had mul-
tilevel disease. Stents were placed in 15 iliac arteries (10%)
and two femoral arteries (1%) at the time of primary proce-
dures. During the follow-up, 17 limbs (11%) had subse-
quent infrainguinal bypass, four (3%) had subsequent open
patch angioplasty procedures, and 41 (27%) had subse-
quent catheter-based angioplasty.
Changes in procedures and outcomes according to
the three periods. Patients in the first period were more
likely to have diabetes mellitus with or without hypoglyce-
mic medications or insulin therapy, a smoking history, and
severe TASC lesion types (P  .05). Patients in the third
period were more likely to have hypertension and hyperlip-
idemia (P  .05) (Table II). Additionally, the complication
rate was significantly higher (P  .05) and the mean
hospital stay was significantly longer (P  .05) in the first
period compared with the second and third periods. Oth-
erwise, comorbidities, technical success, and clinical success
were similar among the three time periods.
The changes in primary and subsequent procedures
over the three periods are summarized in Fig 1 and Appen-
dix III, A-C (online only). Between the first and third
period, the number of endovascular revascularization pro-
cedures done as primary and subsequent procedures signif-
icantly increased from 15 to 84 (460%) and from 13 to 57
(340%), whereas the number of open surgical bypass
procedures done as primary and subsequent procedures
decreased from 39 to 20 (49%) and from 35 to 18
(49%), respectively (P  .0001). Accordingly, the pro-
portion of the endovascular procedures significantly in-
creased in both the primary (from 28% to 81%) and subse-
quent (from 27% to 76%) procedure groups between the
first and third period (P  .0001).
Changes in combinations of primary and subsequent
procedures performed in each limb during the follow-up
were angioplasty alone (primary endo with or without
subsequent endo), 13 limbs (24%) in the first period, 41
limbs (52%) in the second period, and 78 limbs (75%) in the
third period; open surgical bypass alone (primary open with
or without subsequent open), 24 (44%) in the first period,
12 (15%) in the second period, and 15 (14%) in the third
period; and both (primary endo followed by subsequent
open or primary open followed by subsequent endo), 17
(32%) in the first period, 26 (33%) in the second period,
and 11 (11%) in the third period (Fig 2). These results
indicated that the number of patients who were treated by
angioplasty alone (without open surgery) throughout their
follow-up period significantly increased according to the
three periods (P  .05).The respective outcomes (rates  SE) in the first,
second, and third periods at 3 years were cumulative pri-
mary patency, 39%  8%, 48%  7%, and 55%  9%;
assisted primary patency, 53% 8%, 72% 6%, and 86%
4%; secondary patency, 69%  8%, 74%  6%, and 90% 
3%; continued clinical improvement, 53% 8%, 61% 7%,
and 68% 5%; and limb salvage, 93% 4%, 83% 5%, and
92%  3% (Fig 3, A-C and Appendix IV, online only).
The assisted primary patency rates in the third period
were significantly higher than those in the first and second
periods (P  .012); otherwise, there was no statistical
difference in long-term outcomes among the three periods.
The survival rates of patients in the first, second, and third
periods at 5 years were 46%  9%, 47%  7%, and 53% 
11%, respectively (P  .5).
Outcomes according to types of the primary proce-
dures: angioplasty vs surgical bypass. The bypass group
had more comorbidities (hypertension and cerebrovascular
disease), severe TASC lesion types, and distal lesions com-
pared with the endo group (P  .05) (Table I). The
complication rate was significantly less (1% vs 7%), and the
mean hospital stay was significantly shorter in the endo
group (2.6 days vs 7.7 days) than in the bypass group (P
.05). Otherwise, comorbidities, initial technical success,
and clinical success were similar between the two groups.
The outcomes (rates  SE) in the endo and bypass groups
at 5 years were cumulative primary patency, 44% 8% and
28% 8%; assisted primary patency, 85% 3% and 50%
7%; secondary patency, 88%  3% and 57%  7%; contin-
ued clinical improvement, 56%  8% and 39%  8%; and
limb salvage, 91%  3% and 77%  7% (Fig 4 and Appendix
V, online only). The assisted primary and secondary pa-
tency rates in the endo group were significantly higher than
those in bypass group (P  .01); otherwise, there was no
statistical difference in long-term outcomes between the
two groups. The survival rates of patients in the endo and
bypass groups at 5 years were 48%  7% and 46  7%,
respectively (P  .5).
The data were further divided into three groups based on
anatomic locations at the most distal arteries treated (ie, iliac,
femoropopliteal, and tibial groups) and compared between
the endo andbypass groups. In the endogroup, 48 limbswere
classified into the iliac group, 50 into the femoropopliteal
group, and 55 into the tibial group; and in the bypass group,
nine were classified into the iliac group, 34 into the femoro-
popliteal group, and 41 into the tibial group (Table I). The
tibial-endo group had significantly higher assisted primary
patency rates compared with the tibial-bypass group (P 
.041) (Fig 5); otherwise, long-term outcomes, including pri-
mary, assisted primary, and secondary patency, continued
clinical improvement, and limb salvage rates were similar
between iliac-endo and iliac-bypass groups, femoropopliteal-
endo and femoropopliteal-bypass groups, and tibial-endo and
tibial-bypass groups (P .1).
Multivariate analysis. Cox regression analysis identi-
fied several independent simultaneous predictors associated
with outcomes (Table III). Predictors that were associated
with adverse outcomes were age, hypertension, smoking
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for surgery (ulcer/gangrene), TASC classification (typeD),
and the primary procedure type (endo). For overall sur-
vival, femoropopliteal as the most distal artery treated
(compared with tibial or iliac) was associated with improve-
ment, but for primary patency, assisted primary patency,
and secondary patency the most distal artery treated (fem-
oropopliteal or tibial vs iliac) showed adverse outcomes.
The original ABI and the third study period were associated
with improved outcomes.
Both primary procedure types (endo or open bypass)
and study periods were not identified as independent simul-
taneous predictors for secondary patency, clinical improve-
ment, limb salvage, and survival.
DISCUSSION
With continuing improvements in endovascular
Table II. Characteristics of the 237 subjects with critical l
First period




Mean age (years) 69.8  11.9
Comorbidities
Hypertension 38 (70)
Diabetes mellitus 41 (76)
Coronary artery disease 36 (67)
Smoking 33 (61)
Hyperlipidemia 7 (13)
CRF with HD 10 (19)
Cerebrovascular disease 14 (26)
COPD 6 (11)
Indication




Type B 2 (4)
Type C 21 (39)
Type D 31 (57)
The most distal artery treated
Iliac artery 8 (15)
Femoropopliteal artery 21 (39)
Tibial or more distal arteries 25 (46)
Primary procedures
Endo 15 (28)
Open bypass 39 (72)
Subsequent procedures
Endo 13 (27)
Open bypass 35 (73)
ABI 0.37  0.20
Technical success 54 (100)
Clinical success 54 (100)
Complication 6 (11)
Mean hospital stay (days) 5.3  4.3
CRF, Chronic renal failure; HD, hemodialysis; COPD, Chronic obstru
Ankle-brachial pressure index.
Values are indicated with percentages (%) or  SD.
*2 test.
†Kruskal-Wallis test.technology and expertise, an increasing proportion ofpatients with CLI can be treated by angioplasty.4 We
previously reported our results of angioplasty for CLI. 6
Our data in that report demonstrated that long-term
limb salvage rates were high, which was attributed to
high assisted primary and secondary patency rates despite
a low primary patency rate. We concluded that angio-
plasty could be the primary choice for the management
of CLI because the purpose of treatment in this popula-
tion is limb salvage and symptom relief. However, de-
spite an increasing number of iliac and infrainguinal
angioplasty procedures with or without stenting being
performed for CLI in our practice and as these proce-
dures are replacing open bypass surgery more frequently,
we were uncertain precisely how our practice had shifted
from open bypass surgery to endovascular procedures
and whether our outcomes for the treatment of patients
with CLI were affected. We thus considered it important
ischemia
Second period
(n  79) (%)
Third period
(n  104) (%) P*
48 (61) 62 (60) .93
31 (39) 42 (40)
69.0  9.5 70.0  13.4 .89
43 (54) 80 (77) .0049*
54 (68) 54 (52) .0058*
48 (61) 68 (65) .74
33 (42) 41 (39) .026*
25 (32) 50 (48) .0001*
15 (19) 27 (26) .42
15 (19) 15 (14) .83
7 (9) 12 (12) .21
32 (41) 36 (35) .77
47 (59) 68 (65)
0 0 .034†
4 (5) 12 (12)
36 (46) 54 (52)
39 (49) 37 (36)
22 (28) 27 (26) .25
30 (38) 33 (32)
27 (34) 44 (42)
54 (68) 84 (81) .0001*
25 (32) 20 (19)
25 (50) 57 (76) .0001*
25 (50) 18 (24)
0.42  0.24 0.39  0.27 .1
77 (97) 103 (99) .59
73 (92) 98 (94) .13
2 (3) 1 (1) .016*
3.6  5.2 4.6  8.5 .0006†
ulmonary disease; TASC, TransAtlantic Inter-Society Consensus; ABI,imb
ctive pto review the results of our patients with CLI and to
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ization and outcomes in these patients.
In this study, our database including cases with open
bypass and endovascular procedures was analyzed in a
different way to investigate two new hypotheses: (1) there
Fig 1. Trends of primary and subsequent procedures. The num-
ber of procedures in each time period are shown. P values were
calculated with the 2 test.
Fig 2. Trends in combinations of primary and subsequent proce-
dures performed in each limb during the follow-up. The number of
combinations—primary endo with or without subsequent endo
(endo alone), primary open bypass surgery with or with out subse-
quent open (open alone), or primary endo followed by subsequent
open or primary open followed by subsequent endo (both) in each
time period are shown. P was calculated via the Mann-Whitney U
test. Endo, Angioplasty with or without stenting; open, bypass
surgery and/or patch angioplasty.is a distinct and specific changing pattern of revasculariza-tion procedures in patients with CLI, and (2) our outcomes
have not deteriorated but may even have improved in the
treatment for CLI. The identification of these results is
clinically important because this information would predict
the type of treatment that would be best suited for these
patients or these types of patient in the future.
Our findings demonstrated that the number of endo-
vascular procedures done as primary procedures dramati-
cally increased by 460% from the first period to the third
period, whereas the number of open surgical bypass proce-
dures decreased by 50%. Accordingly, the proportion of
endovascular procedures significantly increased from 28%
to 81%. In the presidential address in 1996, Dr Frank
Veith15 predicted that 40% to 70% of peripheral vascular
cases would be done as endovascular procedures. Surpris-
ingly, our results exceeded his prediction, even in this
complex group. When we look at annual procedure vol-
ume, angioplasty procedures increased from 0% in 1993 to
95% in 2004 on the basis of limbs and from 17% in 1993 to
94% in 2004 on the basis of procedures. The inflection
point was between 1995 and 1996.
The changes in our “personal” (single surgeon) results for
treatment of CLI is similar to those of other reported institu-
tional and national results in patients with CLI or general
peripheral vascular disease.4,16-18 Nasr et al4 reported their
institutional results in patients with CLI. They found primary
angioplasty rates significantly increased from 44% (1994 to
1995) to 69% (1998 to 1999), and open surgical revascular-
ization rates decreased correspondingly. Their proportion of
angioplasty procedures was very similar to our results in the
first and second periods in our study (1993 to 2000). In our
series, however, the trend of increasing volume of endovascu-
lar procedures has continued, and the third period (2001 to
2004) showed a further significant increment in the number
of endovascular procedures done.
Anderson et al16 assessed the national changes in inpa-
tient procedures done for vascular diseases between 1980
and 2000. They reported the number of catheter based
procedures dramatically increased by 700% between
1990 and 2000. On the other hand, the number of open
lower extremity revascularization procedures decreased by
15% in the same period.
Wieslander et al17 also assessed the national changes in
the number of annual inpatient procedures done for car-
diovascular diseases. In their results, the annual volume of
catheter-based procedures done for peripheral vascular dis-
eases increased by 44%, much more than the 14% for
peripheral open bypass procedures from 1993 to 1997.
Finally, Sullivan et al18 reported their institutional
changes in open surgical and endovascular procedures for
peripheral vascular disease between 1996 to 2000. They
found that the number of endovascular procedures in-
creased by 324%, whereas the number of open surgical
bypass procedure plateaued and dropped.
None of these previous reports assessed the changes in
subsequent procedures. We found in our series that the
changes in the types of subsequent procedures done for
CLI were similar to that of the primary procedures (ie, a
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decrement of open surgical bypass procedures). This dem-
onstrates that even after failure of a primary revasculariza-
tion procedure, an endovascular procedure is similarly fea-
sible as when an endovascular procedure is used as the
primary procedure.
Nasr et al4 also reported that limb salvage rates were
similar throughout their study period, which agrees with
our results; however, they did not evaluate other outcomes,
such as patency and continued clinical improvement. We
reviewed these outcomes in each period and found that
patency, continued clinical improvement, and limb salvage
rates were also similar or improved during the three periods
even though the types of procedures being done signifi-
cantly shifted to endovascular procedures. These resultssupport our second hypothesis: “our outcomes have not
deteriorated in the treatment for CLI according to the
change of procedures,” and support the judgment that we
can shift the treatment of CLI to less invasive procedures
without compromising the results.
Interestingly, during the three periods, the proportion
of TASC type B andC lesions treated significantly increased
(4% to 12% for type B and 39% to 52% for type C), while the
proportion of TASC type D lesions significantly decreased
(57% to 36%). Thus, it appears that patients with CLI are
possibly being referred to us in an earlier stage of their
disease. This might be because patients were more likely to
accept an endovascular procedure because of its less inva-
siveness rather than an open bypass procedure. Regardless,
Fig 3. Kaplan-Meier life-table analysis of outcomes for critical
limb ischemia in each study period (54 limbs in 1993 to 1996, 79
in 1997 to 2000, and 104 in 2001 to 2004). A, Primary patency.
B, Assisted primary patency. C, Continued clinical improvement.
The assisted primary patency rates were significantly higher in
2001 to 2004 compared with those in 1993 to1996 and 1997 to
2000 (P  .012). The dashed line is the portion of plot where the
standard error (SE) 10%.earlier intervention may result in better outcomes.
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multaneous predictors associated with outcomes. Among
them, the endovascular therapy was an independent simul-
taneous predictor for a decrease in the primary patency
failure rates. However, types of the primary procedures
were not identified as an independent simultaneous predic-
tor for the other outcomes investigated. Given the 5-year
mortality rate was 53% in this study, a clinical benefit
(symptomatic improvement and limb salvage) from a treat-
ment procedure may be more important than better long-
term primary patency for patients with severe CLI symp-
toms.6 Therefore, replacing open surgical bypass
procedures with endovascular procedures does not appear
to compromise our goals for treatment of CLI.
The current study has some shortcomings. The data
described in this report are a single vascular surgeon’s
experience. Patient selection therefore might be biased by
the surgeon’s technical ability, the types of referrals from
primary physicians, and the surgeon’s judgment about theprocedure types. It was possible that owing to the surgeon’s
reputation of advanced endovascular skills, primary physi-
cians were more likely to refer patients who were suitable
for or wished to undergo endovascular surgery rather than
open bypass surgery. However, despite these limitations,
the data illustrate specific changes in the types of proce-
dures done for CLI and allow one to make a good estima-
tion of the future needs of skills needed for vascular surgery
practice that must be acquired during training.
An additional bias of this series is the inferior outcomes
observed in the surgical bypass group, which might be
related to the high percentage of prosthetic graft usage.
When we excluded patients with aortoiliac reconstruction,
respective outcomes for infrainguinal arterial reconstruc-
tions in the bypass group (n  75) and endo group (n 
105) at 5 years were primary patency, 27% and 44%; assisted
primary patency, 50% and 80%; secondary patency; 57% and
83%; and limb salvage rate, 74% and 91%. Outcomes at 5
Fig 4. Kaplan-Meier life-table analysis of outcomes for critical
limb ischemia in the endo group (n  153) and the bypass group
(n  84). A, Primary patency. B, Assisted primary patency. C,
Continued clinical improvement. The assisted primary patency
rates were significantly higher in the endo group compared with
those in the bypass group (P  .0001). The dashed line is the
portion of plot where standard error (SE) 10%.years for infrainguinal bypass with vein grafts for CLI in
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tency, 39% to 61%; assisted primary patency, 58% to 82%;
secondary patency; 60% to 73%; and limb salvage rate, 78%
to 92%.19-21 These rates were higher than those in the
bypass group in the current series and compatible to those
in the endo group. Regardless, these comparisons of the
results support the conclusion that the changing pattern of
angioplasty procedures replacing surgical bypass procedure
has occurred “without compromising the outcomes.”
Selection bias may have occurred in the treatment of
infrainguinal disease, with the more favorable lesions
(shorter lesions, less diffuse disease) being treated with
angioplasty; however, procedure type was not selected
based on anatomic factors alone. Additionally, results of a
multicenter, randomized controlled trial for the treatment
of critical limb ischemia has recently been published from
the United Kingdom.22 The authors reported that in pa-
tients presenting with severe limb ischemia due to infrain-
guinal disease who were suitable candidates for bypass
surgery and angioplasty, a bypass-surgery-first strategy and
a balloon-angioplasty-first strategy were associated with
broadly similar outcomes in terms of amputation-free sur-
vival, although bypass surgery first was more expensive in
the short-term. We believe the results from that study
support our approach for the treatment of CLI.
CONCLUSION
In our experience, open bypass surgery has been largely
replaced over the years by angioplasty as the primary and
subsequent procedure for treatment of CLI without com-
promising outcomes, although it should be acknowledged
that the results of our comparative analyses might be biased
Fig 5. Kaplan-Meier life-table analysis of the assisted primary
patency rates in patients with tibial occlusive disease. There were
55 in the tibial-endo group and 41 tibial-bypass group. There was
a statistical difference between the two groups (P  .041). The
dashed line is the portion of plot where standard error (SE)10%.by relatively poor surgical results possibly due to the highnumber of prosthetic grafts used. Angioplasty is a feasible,
safe, and effective procedure and can be the primary choice
for revascularization of CLI. Open bypass surgery can be
reserved for lesions technically unsuitable for endovascular
procedures and patients who do not demonstrate clinical
improvement after angioplasty. Thus, our data suggest the
importance of teaching and learning endovascular skills as
well as open surgical skills so that all treatment options will
be available to patients with CLI.
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Rate Ratio 95% CIs P
Primary patency
Hypertension 1.77 1.03-3.06 .04
Smoking history 1.82 1.11-2.98 .017
Original ABI 0.27 0.1-0.78 .016
TASC classification
Type D 1.67 1-2.79 .048
Period
Third (2001-2004) 0.57 0.34-0.95 .032
The primary procedures
Endo group 2.08 1.21-3.58 .008
The most distal artery treated
FP 1.82 0.99-.33 .053
T 2.12 1.11-.05 .024
Assisted Primary Patency
TASC classification
Type D 3.72 1.9-.29 .001
Period
Third (2001-2004) 0.51 .26-1 .051
The most distal artery treated
FP 4.91 1.69-14.25 .003
T 3.19 1.1-9.29 .033
Secondary Patency
TASC classification
Type D 3.58 1.72-7.45 .001
The most distal artery treated
FP 15.66 2.09-117.17 .007




Ulcer/gangrene 1.87 1.09-3.2 .023
TASC classification
Type D 1.9 1.17-3.08 .009
Limb Salvage
CRF with HD 3.63 1.43-9.23 .007
Original ABI 0.03 0-0.21 .001
Survival
Age 1.06 1.04-1.09 .001
Smoking history 1.88 1.12-3.16 .017
Original ABI 0.05 0.01-0.18 .001
The most distal artery treated
Femoropopliteal 0.51 0.29-0.89 .019
CIs, Confidence intervals; TASC, TransAtlantic Inter-Society Consensus;
ABI, ankle-brachial pressure index; FP, femoropopliteal artery; T, tibial or
more distal artery; CRF, chronic renal failure; HD, hemodialysis.
*Cox proportional hazards model. Multivariate risk (failure rate) ratios are
given for each factor controlling for the other factors in the model.omathematical Consulting Clinic, Department of Bi-
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